Trial Profile
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Acronyms KONTINUE
- Sponsors Vertex Pharmaceuticals
- 10 May 2016 Status changed from active, no longer recruiting to completed.
- 23 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 30 Jun 2014 Interim results published in a Vertex Pharmaceuticals Media Release.